Author
Department of Chemistry/ College of Education for Pure Science,Tikrit University, Iraq.
Abstract
Objective: Breast cancer is the most common cancer in women next to cervical cancer. Multiple factors are associated with an increased risk of developing breast carcinoma. The aim of this study was to evaluate the hormonal and biochemical parameters of pre- and postmenopausal women affected with breast cancer. Methods: This study included 30 patients with per-treatment BC stage III consisted of (15 premenopausal and 15 postmenopausal women), also 40 women (20 premenopausal and 20 postmenopausal) were age matched apparently healthy control subjects on routine checkup. Premenopausal women (patients and control) were age ranged (40±8) years and postmenopausal women with mean age ranged (60±10) years. Patients and control have biochemical assay of lactate dehydrogenase, alkaline phosphatase, γ-glutamyl transferase , superoxide dismutase , prolactin , estrogen and lipid profile (total cholecterol, triacylglycerol, high density lipoprotein-cholecterol, very low density lipoprotein and low density lipoprotein- cholesterol). Samples were collected from January 2017 to June 2017 of Tikrit Teaching Hospital. Results and Conclusions:- Levels of lactate dehydrogenase, alkaline phosphatase, γ-glutamyl transferase , prolactin , estrogen and lipid profile (except high density lipoprotein- cholecterol ) were increased in serum of pre- and postmenopausal patients when compared with control but superoxide dismutase and high density lipoprotein-cholesterol , were decreased in serum of pre- and pos-tmenopausal patients when compared with control . These data showed that lactate dehydrogenase, alkaline phosphatase, γ-glutamyl transferase, superoxide dismutase, estrogen and triacylglycerol will be reliable markers in breast cancer and can be used as differential diagnostic in both of pre- and postmenopausal women.
Keywords
- breast cancer
- lactate dehydrogenase
- alkaline phosphatase
- γ-glutamyl transferase
- superoxide dismutase
- prolactin
- Estrogen
- Lipid profile
Main Subjects
1-Ferlay J, Parkin DM and Steliarova-Foucher E (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4): 765–81.
2-Sharma GN, Dave R, Sanadya J, Sharma P , K. K Sharma(2010).Various types and management of breast cancer. J Adv Pharm Technol Res. 1(2): 109–126.
3- Chandrakanth KH, Nagra J, Jayaprakash Murthy, Satishkumar, Anand P(2011). Studay of serum levels of GGT, LDH, malondialdehyde and vitamin-E in breast cancer. Inter J Pharm Bio Sci 2(4):489-498.
4- Agrawal A, Gandhe M B, Gupta D, ReddyM V R(2016). Preliminary study on serum Lactate dehydrogenase (LDH)-prognostic biomarker in carcinoma Breast. J Clin Diagn Res. 10(3): BC06–BC08.
5- Vinzenz K, Schöntha E, Zekert F, Wunderer S(1987). Diagnosis of head and neck carcinomas by means of immunological tumour markers (Beta‑2‑microglobulin, immunoglobulin E,ferritin, N‑acetyl‑neuraminic acid, phosphohexose‑isomerase). J Craniomaxillofac Surg 15(5):270‑7.
6- Liu X, Meng Q H , Ye Y , Hildebrandt M A T , Gu J , Wu X(2015).Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic breast cancer. Carcinogenesis 36( 2): 243–248.
7- Shrivastava S , Singh N, Nigam A K , Kumar S , Singh S , Shrivastava R(2016). Serum Alkaline phosphatase level as a better predictor for metastatic breast cancer in comparison to Acid phosphatase and Calcium activities. IOSR-JDMS 15( 12 ): 15-19.
8- Singh A K , Pandey A, Tewari M, Kumar R, Sharma A, Singh K A, Pandey H P, ShuklaH S(2013).Advanced stage of breast cancer hoist alkaline phosphatise activity: risk factor for females in India. Biotech 3(6):517–520.
9- Shackshaft L, Van Hemelrijck M, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I , Wulaningsih W(2017). Circulating γ- glutamyl transferase and development of specific breast cancer subtypes: findings from the apolipoprotein mortality risk cohort. Breast Cancer Res 19(1):22-27.
10- Fentiman IS (2012). GGT: risk and prognosis of cancer. BJC 106(9): 1467–1468.
11- Tsai SM, Hou MF, Wu SH, Hu BW, Yang SF, Chen WT, Chai CY, Ma H, Tsai LY (2011).Expression of manganese SOD in patients with breast cancer. Kaohsiung J Med Sci 27(5): 167-172.
12- Sahu A, Varma M and Kachhawa K (2015). A prognostic study of MDA, SOD and catalase in breast cancer patients. IJSR 4 ( 5):157-159.
13- Germain D(2011). Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North A. 40(3):473-84.
14- Missmer SA, Eliassen AH, Barbieri RL Hankinson SE (2004). Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(4):1856 – 65.
15- The endogenous hormones and breast cancer collaborative group( 2002). Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606 – 16.
16- Faupel-Badger J M, Sherman M E, Garcia-Closas M, Gaudet M M, Falk R T, Andaya A, Pfeiffe R Mr, Yang XR, Lissowska J, Brinton L A, Peplonska B, Vonderhaar B K, Figueroa J D(2010). Prolactin serum levels and breast cancer : relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case–control study from Poland. Brit J Cancer 103(7):1097 – 1102.
17-Macias H and Hinck L (2012). Mammary gland development. Wiley Interdiscip Rev Dev Biol 1(4): 533–557.
18- Eliassen AH, Tworoger SS , Hankinson SE( 2007) .Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 120(7):1536– 1541.
19- Su X, Hankinson S E, Clevenger C V, Eliassen A H, Tworoger S S(2009). Energy balance, early life body size, and plasma prolactin levels in postmenopausal women. Cancer Causes Control 20(2): 253–262
20- Varma M, Sahu A, Paneri S , Kachhawa K (2014).Study of BMI, lipid profile and CBC in women having breast cancer. J Pure App Microbiol 8(6): 4827-4831.
21- Owiredu W K R A, Donkor S, Wiae Addai B ,Amidu N( 2009).Serum lipid profile of breast cancer patients .Pak J Biol 12(4):332-338.
22- Abdelsalam K E A, Hassan I K, Sadig I A(2012). The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci 17(6):562-5.
23- Rodrigues dos Santos C, Fonseca I, Dias S , Mendes de Almeida JC(2014). Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC 14:132-142.
24-Nelson ER, Wardell SE, Jasper JS, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013). 27-Hydroxycholesterol links hyper-cholesterolemia and breast cancer pathophysiology. Science 342(6162):1094–1098.
25- Ray G and Hussain SA(2001). Role of lipids, lipoproteins and vitamins in women with breast cancer.Clin Biochem 34 (1): 71-76.
26-Laisupasin P, Thompat W, Sukarayodhin S , Adisak Sornprom, Sudjaroen Y(2013).Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians 5(1): 38–41.
27- Marklund S and Marklund G(1974). Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47(3), 469-474.
28- Anckaert E, Mees M, Schiettecatte J, Smitz J (2002). Clinical validation of a fully automated 17β-estradiol and progesterone assay (VIDAS®) for use in monitoring assisted reproduction treatment. Clin Chem Lab Med 40(8):824-831.
29- Rajeswari G, Srinivas P S, Rama Krishna K. S ,Suresh E (2016). Study of serum LDH and GGT levels in carcinoma breast. IJBA R 7(1): 031-034.
30- Swetha N, Arul Senghor K A , Ramachandran K(2013) .Serum lactate dehydrogenase and lipid profile in breast cancer. IJPBS 3( 2) : 423-432.
31-Erickson RJ and Morales DR(1061). Clinical use of lactate dehydrogenase. N Eng J Med 265(11): 531-534.
32- Pereira T,Shetty S, Pereira S (2015) . Estimation of serum LDH level in patients with oral premalignant lesions/ conditions and oral squamous cell carcinoma: A clinicopathological study. JCRT 11(1) :78-82.
33- Mishra S, Sharma D C ,Sharma P (2004). Studies of biochemical parameters in breast cancer with and without metastases, IJCB 19 (1): 71-75.
34- Rosalki SB (1975). Gamma-glutamyl transpeptidase. Adv Clin Chem 17:53–107.
35- Kunutsor S K , Apekey T A , Van Hemelrijck M , Calori G, Perseghin G(2015). Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: Systematic review and meta-analysis.Int J Cancer 136(5):,1162–1170.
36- El-Bindary A A, Yahya R S, EL-Mezayen H A, Darwishd H, Eissae M A (2013). Antioxidants status in breast cancer patients under therapy. Ame J Res Com 1(7):152-163.
37-Rose D P and Pruitt B T (1981).Plasma prolactin levels in patients with breast cancer. Cancer 48:2687-2691.
38- Tworoger S S, Sluss P , Hankinson S E(2006). Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women . Cancer Res 66 (4):2476-2482.
39- Henderson B E, Ross R , Bernstein L (1988). Estrogens as a cause of human cancer. Cancer Research 48(2): 246-253.
40- Gorvin C M(2015). The prolactin receptor: Diverse and emerging roles in pathophysiology. J Clin Transl Endocrinol. 2(3): 85–91.
41- DallG V and Britt K L(2017). Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front Oncol. 7: 110-120.
42- Raheem S N A, Atoum M, AL-Hourani H , Rasheed M, Nimer N, Almuhrib T (2010). Relationship between plasma progesterone, estradiol and prolactin concentrations and breast cancer in pre and postmenopausal women. Neoplasma 57( 1) : 74-78.
43- Coscia E B, Sabha M, Gerenutti M , Groppo FC, Bergamaschi CC (2017). Estrone and estradiol levels in breast cancer patients using anastrozole are not related to body mass index. Rev Bras Ginecol Obstet 39(1):14–20.
44- Chumsri S, Howes T, BaoT , Kao Y C , C Yang C(2011). A. aromatase, aromatase inhibitors, and breast cancer . J Steroid Biochem Mol Biol 125(1-2): 13–22.
45- DebebY G and Berihu B A(2015). Review on the role of estrogen receptors in breast cancer. IJPSR 6 (8 ):1100-1104.
46- Llanos A A, Tucker C A ,Shields P G (2012). Cholestrol, lipoprotins, and breast cancer risk in African American women. Ethnicity Disease 22(3):281-287.
47- Zhao Y, Wang H, Pan Y, Li N , Bian C(2016). Association of lipid profile levels in premenopausal and postmenopausal women with breast cancer. Int J Clin Exp Med 9(2):552-563.
48- Ni H, Liu H and Gao R (2015). Serum lipids and breast cancer risk: A meta- analysis of prospective cohort studies. PLoS ONE 10(11): e0142669.
49- Ghahremanfard F, Mirmohammadkhani M, Shahnazari B , Gholami G, Mehdizadeh J (2015) .The valuable role of measuring serum lipid profile in cancer progression. Oman Medical Journal 30( 5): 353–357.
50-Peela J R, Jarari A M, Alsoaeiti S O, El Busaifi S, El Awamy H, Srikumar S(2012). The relationship between serum lipids and breast cancer in Libya. Biochem Anal Biochem 1(6) :117-119.
51- Bani IA, Williams CM, Boulter PS , J. W. Dickerson (1086). Plasma lipids and prolactin in patients with breast cancer. Br J Cancer 54(3):439-46.
52- Haritwal A K, Chourasia R K and Ojha S (2015). A comparative study of serum lipid profile and glucose level between breast cancer patients and controls at tertiary care hospital in India. Inter J Med Sci Res Pra 2 ( 1 ): 16-19.
53- Hussain DAS, Ahmed S, Hoque M , Rabbi S M R, Masood S, Shafi T, Parvin T, Chaudhury H S(2013). Biochemical factors associated with breast cancer in Bangladeshi women. Bangladesh J Med Biochem 6(2): 58-62 .
54 - Nelson E R, Chang C, McDonnell D P (2014). Cholesterol and breast cancer. Pathophysio Tre Endocrinol Metab 25(12): 649–655.
55- Martin L M, Melnichouk O, Huszti E , Connelly P W, Greenberg C V, Minkin S, Boyd N F(2015). Serum lipids, lipoproteins, and risk of breast cancer: A nested case-control study using multiple time points. J Natl Cancer Inst 107(5):1-9.
56- Kabat GC, Kim M, Chlebowski RT , Khandekar J, Ko M G, McTiernan A, Neuhouser M L, Parker D R, Shikany J M, Stefanick M L, Thomson C A, Rohan T E(2009). A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Canc Epidemiol Biomarkers Prev 18(7):2046–2053.
57- Steinhagen-Thiessen E, Bramlage P, Losch C , Hauner H, Schunkert H, Vogt A, Wasem J, Jöckel K H, Moebus S(2008). Dyslipidemia in primary care–prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 7(1):31-42.
58- Parra S , Castro A , Masana L (2015). The pleiotropic role of HDL in autoimmune diseases. Clin Invest Arterioscl 27(2):97-106.
Orentreich N(1998). Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev7(6): 83-488.
)
